| Literature DB >> 35460647 |
Colin Klaus1, Matthew Wascher2, Wasiur R KhudaBukhsh3, Joseph H Tien4, Grzegorz A Rempała5, Eben Kenah6.
Abstract
Entities:
Mesh:
Year: 2022 PMID: 35460647 PMCID: PMC9020805 DOI: 10.1016/S1473-3099(22)00155-4
Source DB: PubMed Journal: Lancet Infect Dis ISSN: 1473-3099 Impact factor: 71.421
FigureRole for anti-SARS-CoV-2 antibodies in the disease course of COVID-19
As disease states progress from preinfection through to critical illness (blue boxes), the potential for antibodies to mitigate illness decreases (dark blue arrow) as pathology transitions from being virally mediated, where antiviral acting therapies are most effective (green triangle), to a hyper-inflammatory state best treated with immunomodulatory therapies (orange triangle).